Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
复制标题
DOI：
10.18632/oncotarget.9908
复制
发表时间：
2016-08-23
期刊：
影响因子：
--
通讯作者：
Li Y
中科院分区：
文献类型：
--
作者：
Deng J;Wang L;Chen H;Hao J;Ni J;Chang L;Duan W;Graham P;Li Y
化疗耐药是复发性卵巢癌治疗的主要挑战，是导致治疗失败和不良临床结局的主要原因。了解卵巢癌化疗耐药的机制将有助于预测疾病进展，开发新的治疗方法和个性化的全身治疗。近十年来，越来越多的证据表明上皮间质转化和肿瘤干细胞在卵巢癌耐药和转移中起重要作用。上皮-间质转化和癌症干细胞的治疗有望改善目前的卵巢癌治疗，并延长复发性卵巢癌患者的生存期。在这篇综述中，我们专注于上皮间充质转化和肿瘤干细胞在卵巢癌化疗耐药中的作用，并探讨开发上皮间充质转化和肿瘤干细胞相关疗法对未来卵巢癌治疗的治疗意义。
Chemoresistance is the main challenge for the recurrent ovarian cancer therapy and responsible for treatment failure and unfavorable clinical outcome. Understanding mechanisms of chemoresistance in ovarian cancer would help to predict disease progression, develop new therapies and personalize systemic therapy. In the last decade, accumulating evidence demonstrates that epithelial-mesenchymal transition and cancer stem cells play important roles in ovarian cancer chemoresistance and metastasis. Treatment of epithelial-mesenchymal transition and cancer stem cells holds promise for improving current ovarian cancer therapies and prolonging the survival of recurrent ovarian cancer patients in the future. In this review, we focus on the role of epithelial-mesenchymal transition and cancer stem cells in ovarian cancer chemoresistance and explore the therapeutic implications for developing epithelial-mesenchymal transition and cancer stem cells associated therapies for future ovarian cancer treatment.